Skip to content

Study · Observational study · n = 186 · 2024

5 results

Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.

Buenaventura-Collazos DC, García-Ramos AF, Balcázar-Valencia CM, Aguilar-Londoño C, Coronel-Restrepo N, Monsalve-Arango CY, Cuesta-Castro DP, Ramírez-Rincón A

Frontiers in endocrinology25 Jun 2024

PMID38982987 (opens in a new tab)PMCIDPMC11231389 (opens in a new tab)DOI10.3389/fendo.2024.1372992 (opens in a new tab)PepBankPUB-38982987
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

IntroductionDiabetes stands as one of the leading causes of death worldwide. Glucagon-like peptide-1 receptor agonists rank among the most effective medications for lowering blood glucose and body weight, as well as reducing cardiovascular risk in individuals with diabetes. Observational studies complement experimental evidence in new settings, different populations, and real-world healthcare practices.MethodsA multicentric observational study of adults with type 2 diabetes treated with once-weekly subcutaneous semaglutide in four health centers in Colombia was conducted. The protocol for the present study was not pre-registered.ResultsData from 186 patients were included. Most patients were women (57%) with a mean age of 62.8 ± 12.1 years. One year of once-weekly semaglutide usage was associated with a mean reduction in HbA1C of -1.47% (95% CI -1.76, -1.17), weight loss of -4.23 kg (95% CI -5.34, -3.12), and albumin/creatinine ratio of -18.6 mg/g (95% CI -60.2, -5.9). Approximately half the treated patients achieved a level of HbA1c ≤7% by the end of follow-up. Adverse events were rare and consistent with clinical trial safety profiles.ConclusionIn Colombia, administering semaglutide subcutaneously once a week over a 1-year period led to an average weight loss of 4.2 kg and a decrease of 1.4% in HbA1c.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in Colombia, one year of once-weekly semaglutide was associated with a mean HbA1c reduction of 1.47%.

    In plain wordsIn adults with type 2 diabetes in Colombia, HbA1c was lower after one year of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change after one year
    Study

    n = 186

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    HbA1c change
    −1.47%
    1 year

    Source sentences

    Summary
    One year of once-weekly semaglutide usage was associated with a mean reduction in HbA1C of -1.47% (95% CI -1.76, -1.17), weight loss of -4.23 kg (95% CI -5.34, -3.12), and albumin/creatinine ratio of -18.6 mg/g (95% CI -60.2, -5.9).
    2 context sentences
    Summary · context
    A multicentric observational study of adults with type 2 diabetes treated with once-weekly subcutaneous semaglutide in four health centers in Colombia was conducted.
    Summary · context
    Data from 186 patients were included.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in Colombia, one year of once-weekly semaglutide was associated with a mean weight loss of 4.23 kg.

    In plain wordsIn adults with type 2 diabetes in Colombia, body weight was lower after one year of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change after one year
    Study

    n = 186

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Weight change
    −4.23 kg
    1 year

    Source sentences

    Summary
    One year of once-weekly semaglutide usage was associated with a mean reduction in HbA1C of -1.47% (95% CI -1.76, -1.17), weight loss of -4.23 kg (95% CI -5.34, -3.12), and albumin/creatinine ratio of -18.6 mg/g (95% CI -60.2, -5.9).
    2 context sentences
    Summary · context
    A multicentric observational study of adults with type 2 diabetes treated with once-weekly subcutaneous semaglutide in four health centers in Colombia was conducted.
    Summary · context
    Data from 186 patients were included.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in Colombia, one year of once-weekly semaglutide was associated with a mean albumin/creatinine ratio reduction of 18.6 mg/g.

    In plain wordsIn adults with type 2 diabetes in Colombia, a urine kidney marker was lower after one year of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseAlbumin/creatinine ratio change after one year
    Study

    n = 186

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Albumin/creatinine ratio change
    −18.6 mg/g
    1 year

    Source sentences

    Summary
    One year of once-weekly semaglutide usage was associated with a mean reduction in HbA1C of -1.47% (95% CI -1.76, -1.17), weight loss of -4.23 kg (95% CI -5.34, -3.12), and albumin/creatinine ratio of -18.6 mg/g (95% CI -60.2, -5.9).
    2 context sentences
    Summary · context
    A multicentric observational study of adults with type 2 diabetes treated with once-weekly subcutaneous semaglutide in four health centers in Colombia was conducted.
    Summary · context
    Data from 186 patients were included.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in Colombia, about half of the treated patients reached an HbA1c of 7% or lower by the end of follow-up.

    In plain wordsIn adults with type 2 diabetes in Colombia, about half of the patients on weekly semaglutide reached an HbA1c of 7% or lower.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion reaching HbA1c 7% or lower
    Study

    n = 186

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Approximately half the treated patients achieved a level of HbA1c ≤7% by the end of follow-up.
    2 context sentences
    Summary · context
    A multicentric observational study of adults with type 2 diabetes treated with once-weekly subcutaneous semaglutide in four health centers in Colombia was conducted.
    Summary · context
    Data from 186 patients were included.
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes in Colombia, adverse events with once-weekly semaglutide were rare and consistent with clinical trial safety profiles.

    In plain wordsIn adults with type 2 diabetes in Colombia, side effects of weekly semaglutide were rare and matched those seen in trials.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events
    Study

    n = 186

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Adverse events were rare and consistent with clinical trial safety profiles.
    2 context sentences
    Summary · context
    A multicentric observational study of adults with type 2 diabetes treated with once-weekly subcutaneous semaglutide in four health centers in Colombia was conducted.
    Summary · context
    Data from 186 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.